Shanghai Institute Of Biological Products

This study tests a new shingles vaccine in 645 healthy adults aged 40 and up. Participants receive two doses to see if the vaccine is safe and triggers a strong immune response. The goal is to find a well-tolerated vaccine that prevents shingles in this age group.

This early-stage trial tests a new flu vaccine in 120 adults aged 60 and older. Participants receive either the new vaccine, a standard flu vaccine, or a placebo. The study checks for side effects and measures immune response to see if the new vaccine is safe and works well.

This study tests a new monkeypox vaccine in 120 adults aged 18 and older. The vaccine uses a weakened virus to train the body's defenses. Researchers will check for side effects and measure how well the vaccine triggers an immune response.

This early-stage trial tests a new drug called SIBP-A10 in 160 adults with advanced tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will be closely monitored for side effects a…

This early-phase study tests a new drug called SIBP-A17 in about 196 adults aged 18-75 with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. This is a first-…

This early-stage trial tests a new drug called peguricase, given with methotrexate, in 36 adults with gout that standard treatments can't control. The goal is to check safety, how the body processes the drug, and initial signs of effectiveness. Participants must be 18-70 years ol…

This early-stage study tests a new drug called SIBP-A18 in 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be between 18 and…

This study tests a new drug called SIBP-03 combined with cetuximab in people with advanced head and neck cancer that has returned or spread. Participants must have already tried immunotherapy and platinum chemotherapy. The goal is to see if the combination shrinks tumors and is s…

This early-stage study tests a new drug, SIBP-A19, in 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the drug moves through the body. Participants will receive the drug and …

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or control the disease. Participants …

This study tests a new injection called SIBP-A16 in 140 healthy adults aged 18 to 45. The goal is to see if it is safe and how the body processes it, as a potential way to prevent respiratory syncytial virus (RSV) infection. Participants are randomly assigned to receive the study…